FIELD: medicine, pharmacy.
SUBSTANCE: group of inventions refers to biotechnology, namely to bispecific antibodies, and application thereof. The bispecific antibodies comprise two Fab fragments, the first Fab fragment comprises at least one antigen-binding site specific for the first antigen and the second Fab fragment comprises at least one antigen-binding site specific for the second antigen, where variable regions or constant regions between heavy and light chains of the second Fab fragment are exchanged, at that, the bispecific antibody lacks the Fc domain. A method and a host cell for their preparation as well as a pharmaceutical composition and an immunoconjugate for cancer treatment containing such bispecific antibodies are also proposed. The advantage of the claimed bispecific antibodies is the reduced fragments aggregation, improved stability, and improved efficiency of binding to antigen.
EFFECT: invention allows effective cancer therapy.
13 cl, 23 dwg, 2 tbl, 9 ex
Title | Year | Author | Number |
---|---|---|---|
BISPECIFIC ANTIBODIES SPECIFIC FOR T-CELL ACTIVATING ANTIGENS AND A TUMOR ANTIGEN AND METHODS OF USE | 2012 |
|
RU2605390C2 |
BIOSPECIFIC ANTIGEN-BINDING MOLECULES | 2012 |
|
RU2650775C2 |
CD3-TARGETING ANTIBODY, BISPECIFIC ANTIBODY AND THEIR APPLICATIONS | 2020 |
|
RU2808138C1 |
METHOD FOR SELECTION AND PRODUCTION OF SELECTIVE AND MULTISPECIFIC THERAPEUTIC MOLECULES WITH SPECIFIED PROPERTIES, INCLUDING, AT LEAST TWO, DIFFERENT TARGET GROUPS, AND THEIR APPLICATIONS | 2013 |
|
RU2644263C2 |
BISPECIFIC ANTIBODIES | 2011 |
|
RU2573588C2 |
ANTI-CD3-ANTIBODY AND MOLECULE CONTAINING THIS ANTIBODY | 2017 |
|
RU2790326C2 |
PSMA×CD3 BISPECIFIC SINGLE-CHAIN ANTIBODY HAVING INTERSPECIES SPECIFICITY | 2009 |
|
RU2559531C2 |
MONOVALENT CARRIER MODULES ACROSS BLOOD-BRAIN BARRIER | 2014 |
|
RU2694659C2 |
UNIVERSAL TRANSMITTER MODULES THROUGH THE HEMATOENCEPHALITIC BARRIER | 2014 |
|
RU2799436C1 |
DUAL VARIABLE REGION ANTIBODY-LIKE BINDING PROTEINS HAVING CROSS-OVER BINDING REGION ORIENTATION | 2012 |
|
RU2695880C2 |
Authors
Dates
2017-04-28—Published
2012-08-21—Filed